The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed Tedros Adhanom Ghebreyesus as board chair and Dr Ernest Loevinsohn as vice-chair.
Tedros Adhanom Ghebreyesus
The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed Tedros Adhanom Ghebreyesus as board chair and Dr Ernest Loevinsohn as vice-chair. Tedros Adhanom Ghebreyesus Mr Ghebreyesus has been minister of health of Ethiopia since 2005. He served as chair of the Roll Back Malaria Partnership until May this year, and continues to head the UNAIDS programme co-ordination board. He has also held various roles in advisory groups such as the executive committee of the Partners in Population and Development and the GAVI Alliance. He succeeds Rajat Guptas, partner and former managing director of McKinsey & Company, as board chair. Dr Ernest Loevinsohn Vice-chair Dr Loevinsohn is director general of the Global Initiatives Directorate in the Canadian International Development Agency (CIDA). He was founding chair of the Global Stop TB Partnership, and continues to represent Canada, Germany and Switzerland on the board of the Global Fund. In his vice-chair role he replaces Elizabeth Mataka, executive director of the Zambia National AIDS Network. Both will chair their first board meeting in November.
The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed Tedros Adhanom Ghebreyesus as board chair and Dr Ernest Loevinsohn as vice-chair.
Tedros Adhanom Ghebreyesus
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.